PMV Pharmaceuticals, Inc. (PMVP)
$1.35-4.26%Close
BUYCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $72M
- Beta
- 1.35
- P/E (TTM)
- -0.95
- Short % float
- 5.71%
- Days to cover
- 3.6
- SI change
- -4.3%
- 1W
- -16.15%
- 1M
- -7.53%
- vs SPY 1W
- -16.01%
- vs SPY 1M
- -10.04%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 11
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-46.9%
REV YoY-
ROE-78.1%
EPS YoY-
ROA-91.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.95
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.01
P/FCF-
EV/EBITDA-0.79
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.30
ALTMAN Z-
CURR RATIO7.70
ND/EBITDA-
BETA1.35
Company news
FAQ
- What is LOPJLB’s current signal on PMVP?
- LOPJLB’s latest quantitative signal on PMV Pharmaceuticals, Inc. (PMVP) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is PMVP in?
- PMV Pharmaceuticals, Inc. (PMVP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does PMV Pharmaceuticals, Inc. (PMVP) do?
- PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. T…